PGNYMEDIUM SIGNALREGULATORY10-K

PGNY added new risk language around AI usage and PBM regulatory scrutiny while demonstrating solid operational performance with improved profitability and cash generation.

The company is proactively flagging emerging regulatory risks as it expands into AI-enabled healthcare solutions and faces increased oversight of its pharmacy benefit management operations. The addition of specific language around "increasing scrutiny" and "new or heightened challenges" suggests management is preparing investors for a more complex regulatory environment that could impact future operations.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

PGNY delivered solid financial performance with operating income growing 26.4% and gross profit expanding 20.2%, while operating cash flow improved 17.4% to $210.2M. The company meaningfully reduced share buybacks from $300.3M to $81.7M, contributing to a 30.9% decline in cash reserves to $112.2M. Overall balance sheet growth of 22.3% in assets, liabilities, and equity suggests continued business expansion while maintaining financial stability.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-72.8%
$300.3M→$81.7M

Buyback activity reduced 72.8% — capital being redeployed elsewhere or cash conservation underway.

Cash & Equivalents
Balance Sheet
-30.9%
$162.3M→$112.2M

Cash declined 30.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
+26.4%
$67.5M→$85.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Assets
Balance Sheet
+22.3%
$607.1M→$742.4M

Asset base grew 22.3% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+22.3%
$185.0M→$226.4M

Liabilities increased 22.3% — monitor debt-to-equity ratio and interest coverage.

Stockholders Equity
Balance Sheet
+22.3%
$422.1M→$516.0M

Equity base grew 22.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
+20.2%
$253.4M→$304.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Current Liabilities
Balance Sheet
+20%
$168.6M→$202.4M

Current liabilities rose 20% — increased short-term obligations, watch current ratio.

Operating Cash Flow
Cash Flow
+17.4%
$179.1M→$210.2M

Operating cash flow grew 17.4% — strong conversion of earnings to cash, healthy business fundamentals.

Current Assets
Balance Sheet
+16.7%
$472.7M→$551.8M

Current assets grew 16.7% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
As of January 31, 2026, the registrant had 81,902,232 shares of common stock, $0.0001 par value per share, outstanding.
We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates, which could have an adverse impact on our business.
Our use of artificial intelligence may subject us to new or heightened legal, regulatory, ethical, operational or other challenges.
We are part of the broader healthcare industry and subject to increasing scrutiny, business requirements and regulation within our business, including with respect to Progyny Rx s PBM operations, which may adversely affect our business, financial condition and results of operations.
BUSINESS Overview Progyny is a global leader in women s health and family building solutions.
+7 more — sign up free →
REMOVED
As of January 31, 2025, the registrant had 85,413,283 shares of common stock, $0.0001 par value per share, outstanding.
If we fail to maintain an efficient pharmacy distribution network or if there is a disruption to our network of specialty pharmacies or their supply chains, our business, financial condition and results of operations could suffer.
We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates.
Our mission is to empower healthier, supported journeys through transformative fertility, family building and women's health benefits.
Progyny is a leading benefits management company specializing in fertility, family building and women's health benefits solutions in the United States.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →